Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
JPI-289 by Jeil Pharmaceutical for Myocardial Infarction: Likelihood of Approval
JPI-289 is under clinical development by Jeil Pharmaceutical and currently in Phase II for Myocardial Infarction. According to GlobalData, Phase...